Corcept Therapeutics Incorporated (CORT:NASDAQ) closed at $72.77 on November 6, 2026, up 1.59% on the day. The stock trades 42.4% below its 52-week high of $126.38 and 153.9% above its 52-week low of $28.66. Over the past year, it lost 1.3%. Corcept Therapeutics Incorporated is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 6, 2025, CORT closed higher on 140 days (56%). Its best day was July 30, 2026 (+27.29%) and its worst was December 31, 2025 (-50.43%). The stock moved 10% or more in a single session 11 times. It opened at least 5% above the previous day's high 3 times.
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing's syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortis...
Find more stocks like CORT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.